Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 9, 2026, Edmund Dunn informed us of his intent to retire from the role of SVP, Corporate Controller and Principal Accounting Officer of Monte Rosa Therapeutics, Inc. (the "Company"), effective as of April 3, 2026. Mr. Dunn's retirement and departure from the Company was not because of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Mr. Dunn will not receive any severance payments or benefits in connection with his departure.

Effective April 3, 2026, Matthew Bowen, currently an employee of the Company, will succeed Mr. Dunn as Corporate Controller and Principal Accounting Officer of the Company. Mr. Bowen, age 37, joined the Company's finance department following the Company's initial public offering in June 2021 to support the enhanced financial reporting and compliance requirements associated with operating as a public company. Since joining the Company, Mr. Bowen has served in roles of increasing responsibility over the past nearly five years, most recently as Director, Finance. Prior to joining the Company, Mr. Bowen spent seven years in the audit and assurance practice at Ernst & Young LLP, where he primarily worked on audits of large public companies. Mr. Bowen holds a Bachelor of Science and a Master's in Accounting from Bryant University and is a licensed Certified Public Accountant in the Commonwealth of Massachusetts.

There are no arrangements or understandings between Mr. Bowen or any other person pursuant to which Mr. Bowen was promoted. There are no family relationships between Mr. Bowen and any other director, executive officer or nominees thereof of the Company. There are no related party transactions between the Company and Mr. Bowen that would require disclosure under Item 404(a) of Regulation S-K under the Exchange Act.